abusesaffiliationarrow-downarrow-leftarrow-rightarrow-upattack-typeburgerchevron-downchevron-leftchevron-rightchevron-upClock iconclosedeletedevelopment-povertydiscriminationdollardownloademailenvironmentexternal-linkfacebookfiltergenderglobegroupshealthC4067174-3DD9-4B9E-AD64-284FDAAE6338@1xinformation-outlineinformationinstagraminvestment-trade-globalisationissueslabourlanguagesShapeCombined Shapeline, chart, up, arrow, graphLinkedInlocationmap-pinminusnewsorganisationotheroverviewpluspreviewArtboard 185profilerefreshIconnewssearchsecurityPathStock downStock steadyStock uptagticktooltiptwitteruniversalityweb
Article

1 Dec 2006

Author:
William Baue, SocialFunds

Pharma Companies Need to Keep Improving AIDS Response, Says ICCR and Nigerian Doctor

In August 2006, the Interfaith Center on Corporate Responsibility (ICCR) produced the most thorough study of pharmaceutical company action on HIV/AIDS, documenting how the industry falls significantly short of best practice...The Business and Human Rights Resource Centre posted the report along with company responses to it on its website. [The following companies sent responses: Abbott Laboratories; AstraZeneca; GlaxoSmithKline; Boehringer-Ingelheim; Bristol-Myers Squibb; Merck; Novartis; Pfizer; Tibotec (part of Johnson & Johnson), Wyeth. The following did not respond: Eli Lilly; Gilead Sciences; Hoffman-La Roche; sanofi-aventis; Schering-Plough.]...[The Resource Centre] recently added a paper by Dr. Chukwumuanya Igboekwu...of Physicians for Social Justice (PSJ) in Nigeria...in which he identifies patent protection...as a persisting problem in pharma companies' response to AIDS...Dr. Igboekwu cites the case of Novartis filing a lawsuit in India to protect patents covering certain of its cancer drugs...The...Resource Centre posted a response...from Novartis...